Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus chemotherapy as neoadjuvant therapy in resectable EGFR-mutant stage II–IIIA NSCLC
ChiCTR2200062769Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Objective response rate and Pathological complete response rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200062769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062769.